Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection.
An extraction method has been developed using benzene sulphonyl cation-exchange sample preparation cartridges and reversed-phase high-performance liquid chromatography with ultraviolet detection for the measurement of S9788, a drug to reverse resistance to anticancer agents, in plasma and serum. This includes a toxicokinetic assay which has a mean precision and accuracy of 11.7% and 7.9%, respectively, over the range 10-1000 ng ml-1 and a quantification limit of 10 ng ml-1 and a more sensitive pharmacokinetic procedure with a mean precision and accuracy of 5.0% and 7.9%, respectively, over the range 1-500 ng ml-1 and a quantification limit of 1 ng ml-1. The specificity of the procedure has been demonstrated by mass and ultraviolet spectrometry, and linearity, precision, accuracy, recovery and sensitivity have been established. The assays have been successfully applied to toxicokinetic and pharmacokinetic studies.
Bakes
D M
DM
Servier Research and Development Ltd., Fulmer, Slough, UK.
Turner
N D
ND
Gordon
B H
BH
Hiley
M P
MP
Walther
B
B
Lucas
C
C
D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000633:toxicity; D002851:Chromatography, High Pressure Liquid; D000882:Haplorhini; D010880:Piperidines / Q000097:blood* / Q000493:pharmacokinetics / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D012015:Reference Standards; D013056:Spectrophotometry, Ultraviolet; D014227:Triazines / Q000097:blood* / Q000493:pharmacokinetics / Q000633:toxicity
D000970:Antineoplastic Agents; D010880:Piperidines; D014227:Triazines; C077022:S 9788